OBJECTIVE: Depression is a proposed risk factor for heart failure based largely on epidemiological data; few experimental data addressing this hypothesis are available. METHODS: Depression was evaluated in relation to cardiac structural and functional phenotypes assessed by transthoracic echocardiography in 42 adult female cynomolgus monkeys that consumed a Western-like diet for 3 years. Half of the monkeys were treated with sertraline HCl for 18 months, and depressive behavior was assessed for 12 months before echocardiography. RESULTS: Depressed monkeys (the 19/42 with depressive behavior rates above the mean rate) had higher heart rates (HRs; 171 [4.1[ versus 152 [6.1]) and smaller body surface area (0.13 [0.003] versus 0.15 [0.004]), left ventricular (LV) end-systolic dimension (0.75 [0.05] versus 0.89 [0.04]), LV systolic (0.76 [0.08] versus 1.2 [0.11]) and diastolic (2.4 [0.23] versus 3.4 [0.26]) volumes, and left atrial volumes (1.15 [0.14] versus 1.75 [0.12]; p values < .05). Doppler profiles of depressed monkeys indicated greater myocardial relaxation (higher e' and higher e'/a' ratio) and lower filling pressures (lower E/e') compared to nondepressed monkeys (p values < .05). Although sertraline treatment reduced HR (150 [5.8] versus 171 [4.8]) and modestly increased chamber dimensions (LV end-systolic dimension: 0.91 [0.05] versus 0.74 [0.03]; LV end-diastolic dimension, body surface area adjusted 1.69 [0.05] versus 1.47 [0.06]; p values < .05), it did not overtly affect systolic or diastolic function (p values > .10). CONCLUSIONS: These data suggest that behavioral depression in female primates is accompanied by differences in cardiac function, although not in ways classically associated with subclinical heart failure. Selective serotonin reuptakes show promise in supporting heart function by reducing HR and perhaps improving LV filling; however, further investigation is needed.
OBJECTIVE:Depression is a proposed risk factor for heart failure based largely on epidemiological data; few experimental data addressing this hypothesis are available. METHODS:Depression was evaluated in relation to cardiac structural and functional phenotypes assessed by transthoracic echocardiography in 42 adult female cynomolgus monkeys that consumed a Western-like diet for 3 years. Half of the monkeys were treated with sertraline HCl for 18 months, and depressive behavior was assessed for 12 months before echocardiography. RESULTS:Depressed monkeys (the 19/42 with depressive behavior rates above the mean rate) had higher heart rates (HRs; 171 [4.1[ versus 152 [6.1]) and smaller body surface area (0.13 [0.003] versus 0.15 [0.004]), left ventricular (LV) end-systolic dimension (0.75 [0.05] versus 0.89 [0.04]), LV systolic (0.76 [0.08] versus 1.2 [0.11]) and diastolic (2.4 [0.23] versus 3.4 [0.26]) volumes, and left atrial volumes (1.15 [0.14] versus 1.75 [0.12]; p values < .05). Doppler profiles of depressed monkeys indicated greater myocardial relaxation (higher e' and higher e'/a' ratio) and lower filling pressures (lower E/e') compared to nondepressed monkeys (p values < .05). Although sertraline treatment reduced HR (150 [5.8] versus 171 [4.8]) and modestly increased chamber dimensions (LV end-systolic dimension: 0.91 [0.05] versus 0.74 [0.03]; LV end-diastolic dimension, body surface area adjusted 1.69 [0.05] versus 1.47 [0.06]; p values < .05), it did not overtly affect systolic or diastolic function (p values > .10). CONCLUSIONS: These data suggest that behavioral depression in female primates is accompanied by differences in cardiac function, although not in ways classically associated with subclinical heart failure. Selective serotonin reuptakes show promise in supporting heart function by reducing HR and perhaps improving LV filling; however, further investigation is needed.
Authors: N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger Journal: J Am Soc Echocardiogr Date: 1989 Sep-Oct Impact factor: 5.251
Authors: Carol A Shively; Thomas C Register; David P Friedman; Timothy M Morgan; Jalonda Thompson; Tasha Lanier Journal: Biol Psychol Date: 2005-01-07 Impact factor: 3.251
Authors: Stephanie L Willard; Beth Uberseder; Ashlee Clark; James B Daunais; Warwick D Johnston; David Neely; Adreanna Massey; Jeff D Williamson; Robert A Kraft; J Daniel Bourland; Sara R Jones; Carol A Shively Journal: Neuropharmacology Date: 2015-06-24 Impact factor: 5.250
Authors: Marnie G Silverstein-Metzler; Jamie N Justice; Susan E Appt; Leanne Groban; Dalane W Kitzman; John Jeffrey Carr; Thomas C Register; Carol A Shively Journal: Menopause Date: 2017-10 Impact factor: 2.953
Authors: Esra Fidan; Z Isik Solak Gormus; İbrahim Kilinc; Mehmet Sinan İyisoy; Niyazi Gormus Journal: Biol Trace Elem Res Date: 2021-03-28 Impact factor: 3.738
Authors: Marnie G Silverstein-Metzler; Brett M Frye; Jamie N Justice; Thomas B Clarkson; Susan E Appt; J Jeffrey Carr; Thomas C Register; Mays Albu-Shamah; Hossam A Shaltout; Carol A Shively Journal: Psychoneuroendocrinology Date: 2022-02-26 Impact factor: 4.905
Authors: Marnie G Silverstein-Metzler; Carol A Shively; Thomas B Clarkson; Susan E Appt; J Jeffrey Carr; Stephen B Kritchevsky; Sara R Jones; Thomas C Register Journal: Psychoneuroendocrinology Date: 2016-02-21 Impact factor: 4.905
Authors: Kristofer T Michalson; Leanne Groban; Timothy D Howard; Carol A Shively; Areepan Sophonsritsuk; Susan E Appt; J Mark Cline; Thomas B Clarkson; J Jeffrey Carr; Dalane W Kitzman; Thomas C Register Journal: J Am Heart Assoc Date: 2018-11-06 Impact factor: 5.501